Kouno, Takahide http://orcid.org/0000-0002-0075-5046
Shibata, Satoshi http://orcid.org/0000-0002-6095-9796
Shigematsu, Megumi http://orcid.org/0000-0003-3265-5557
Hyun, Jaekyung http://orcid.org/0000-0003-2914-537X
Kim, Tae Gyun
Matsuo, Hiroshi http://orcid.org/0000-0002-4559-6157
Wolf, Matthias http://orcid.org/0000-0001-8480-0918
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP18am0101076)
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (R01GM118474, R01AI150478)
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine
Article History
Received: 14 February 2023
Accepted: 29 June 2023
First Online: 7 July 2023
Competing interests
: The authors S.S., J.H., T.G.K., H.S., H.M., and M.W. declare no competing interests. T.K. has filed patents on preparation of the solubility-enhanced human A3G construct, its application for A3G-Vif complex analysis [PCT-JP2019-019938 (2019) and JP patent application number 2021-519919 (2021)]; on DNA/RNA/hybrid-based antagonism against A3G-Vif interaction [PCT-JP2021-42773 (2021)].